JCI table of contents: May 22, 2008(hich was named dendritic cell NK lectin ...),Health

Date:5/22/2008

hich was named dendritic cell NK lectin group receptor-1 (DNGR-1), was an endocytic receptor and that if an antibody that recognizes DNGR-1 was linked to a peptide it delivered the peptide specifically to DCs expressing CD8-alpha. CTL responses directed to the peptide were induced in mice vaccinated with the peptide-linked DNGR-1specific antibody and an adjuvant. Directing these CTL responses toward melanoma cells by linking the DNGR-1specific antibody to peptides from proteins overexpressed by a melanoma cell line eradicated melanoma in a therapeutic mouse model. Further, as expression of DNGR-1 in humans was found to be restricted to a subset of DCs with characteristics similar to mouse DCs expressing CD8-alpha, the authors suggested that targeting DCs via DNGR-1 might provide a new approach to tumor immunotherapy.

TITLE: Tumor therapy in mice via antigen targeting to a novel, DC-restricted C-type lectin

AUTHOR CONTACT:
Caetano Reis e Sousa
Cancer Research UK, London, United Kingdom.
Phone: 44-20-7269-2832; Fax: 44-20-7269-2833; E-mail: caetano@cancer.org.uk.

View the PDF of this article at: https://www.the-jci.org/article.php?id=34584

---

NEUROBIOLOGY: To protect against or to promote, that is the question about the role of the cellular process autophagy in Alzheimer disease

All neurodegenerative disorders (e.g. Alzheimer disease [AD], Parkinson disease, and Huntington disease) are characterized by the presence of protein aggregates in the brain and nerve cell death. Recent data have implicated a cellular process known as autophagy (whereby cells can degrade long-lived proteins and compartments to remodel their interiors and/or survive stressful situations) in neurodegeneration, but whether it protects against or promotes neurodegeneration remains controversial. New data, generated by T
'/>"/>

Contact: Karen Honey press_releases@thje-jci.org 215-573-1850 Journal of Clinical Investigation Source:Eurekalert

0 GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11
Related medicine news :

1. New Survey Suggests That Consumers Are Naive to the Risk of Botox Parties and the Importance of FDA Approval for Cosmetic Injectables
2. Eat Your Vegetables - That Means You, Parents!
3. Biotel Announces Profitable Third Quarter Ended March 31, 2008
4. Mylan Launches Paroxetine Hydrochloride Extended-Release Tablets
5. FDA Approves NOVO NORDISKs NovoSeven(R) RT (Coagulation Factor VIIa [Recombinant] Room Temperature Stable) for Hemophilia Patients With Inhibitors
6. Dawning Technologies, Inc. Releases JavaLin/PDI Portable Device Interface
7. SEIU Members to Politicians: Live Up to Your Promises or We Will Hold You Accountable
8. Dr. Arnold Klein Warns of Dangers With Permanent and Longer Lasting Injectable Fillers
9. Roxane Laboratories, Inc. Announces the Launch of Acarbose Tablets
10. After divorce, stable families help minimize long-term harm to children
11. Pilot study reinforces use of portable anteroom HEPA filtration